WOBURN, Mass., Aug. 15 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that it has appointed Dr. Thaddeus Pullano, 53, as Vice President of Quality Assurance.
(Photo: http://www.newscom.com/cgi-bin/prnh/20070815/NYW022 )
Previously, Dr. Pullano served as the Vice President of Quality Systems for Acambis from 2003 to 2007. In this role, he was responsible for all aspects of Quality Systems, including oversight of vaccine manufacturing and clinical quality assurance. Prior to joining Acambis, Dr. Pullano was responsible for quality assurance at Transkaryotic Therapies as the Company transitioned from R&D to manufacturing operations. He has also held a number of positions in quality assurance at Wyeth Vaccines. Dr. Pullano holds a Ph.D. in Biochemistry from the University of Southern California and a BS in Biochemistry from the State University of New York at Binghamton.
Philip Astley-Sparke, President & CEO of BioVex Inc, said:
“Thad has direct and extensive experience with quality systems supporting the manufacture and release of biologics for clinical trials and commercial sale. He becomes part of the core team dedicated to moving our Woburn manufacturing facility, which will supply Phase III and launch grade material, towards operational status.”
About BioVex
BioVex is a privately held biotechnology Company based in Woburn. MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.
BioVex’s lead cancer program, OncoVEX(GM-CSF), is an oncolytic virus that selectively destroys tumor cells accompanied by the induction of a systemic immune response. OncoVEX(GM-CSF) is currently completing a Phase II clinical trial for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Preliminary data from these studies has been very encouraging demonstrating OncoVEX(GM-CSF) has the potential to treat both local and metastatic disease. The Company is currently preparing for an initial registration study in melanoma where multiple responses have been demonstrated in an ongoing Phase II trial testing OncoVEX(GM-CSF) as stand alone therapy in patients with stage IIIc and stage IV metastatic disease.
The Company’s second program is a vaccine for genital herpes, ImmunoVEX(HSV2), which provides complete protection in animal models of the disease. A Phase I study with ImmunoVEX(HSV2) is scheduled to initiate later this year.
For more information visit the company’s website at www.biovex.com.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20070815/NYW022AP Archive: http://photoarchive.ap.orgAP PhotoExpress Network: PRN8PRN Photo Desk, photodesk@prnewswire.comBioVex
CONTACT: Philip Astley-Sparke, President & CEO of BioVex Inc,+1-781-376-4913, pastleysparke@biovex.com; or Jonathan Birt of FD LifeSciences, +1-212-850-5634, jonathan.birt@fd.com, for BioVex Inc
Web site: http://www.biovex.com/
